Related Experiment Video
Updated: Jun 4, 2026

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
Published on: January 8, 2015
RepA-WH1 prionoid: a synthetic amyloid proteinopathy in a minimalist host
Rafael Giraldo1, Susana Moreno-Díaz de la Espina, M Elena Fernández-Tresguerres
1Department of Chemical and Physical Biology, Centro de Investigaciones Biológicas - CSIC, C/ Ramiro de Maeztu, Madrid, Spain. rgiraldo@cib.csic.es
Abstract:
The intricate complexity, at the molecular and cellular levels, of the processes leading to the development of amyloid proteinopathies is somehow counterbalanced by their common, universal structural basis. The later has fueled the quest for suitable model systems to study protein amyloidosis under quasi-physiological conditions in vitro and in simpler organisms in vivo. Yeast prions have provided several of such model systems, yielding invaluable insights on amyloid structure, dynamics and transmission. However, yeast prions, unlike mammalian PrP, do not elicit any proteinopathy. We have recently reported that engineering RepA-WH1, a bacterial DNA-toggled protein conformational switch (dWH1 → mWH1) sharing some analogies with nucleic acid-promoted PrPC → PrPSc replication, enables control on protein amyloidogenesis in vitro. Furthermore, RepA-WH1 gives way to a non-infectious, vertically-transmissible (from mother to daughter cells) amyloid proteinopathy in Escherichia coli. RepA-WH1 amyloid aggregates efficiently promote aging in bacteria, which exhibit a drastic lengthening in generation time, a limited number of division cycles and reduced fitness. The RepA-WH1 prionoid opens a direct means to untangle the general pathway(s) for protein amyloidosis in a host with reduced genome and proteome.
Insights
Researchers engineered RepA-WH1, a bacterial protein switch, to create a novel amyloid proteinopathy model in E. coli. This system allows studying protein misfolding and its effects on bacterial aging and fitness.
Area of Science:
- Biochemistry
- Molecular Biology
- Microbiology
Background:
- Amyloid proteinopathies share a common structural basis, driving the search for in vitro and in vivo model systems.
- Yeast prions offer insights into amyloid structure and dynamics but do not cause proteinopathies.
- Mammalian PrP protein misfolding is a key factor in neurodegenerative diseases.
Purpose of the Study:
- To engineer a controllable bacterial model for studying protein amyloidogenesis.
- To investigate the impact of amyloid aggregates on bacterial aging and fitness.
- To establish a system for understanding general protein amyloidosis pathways.
Main Methods:
- Engineering the RepA-WH1 bacterial DNA-toggled protein conformational switch.
- Inducing amyloidogenesis in vitro and in Escherichia coli.
- Observing and quantifying bacterial aging phenotypes (generation time, division cycles, fitness).
Main Results:
- RepA-WH1 amyloidogenesis was successfully controlled in vitro.
- A non-infectious, vertically-transmissible amyloid proteinopathy was established in E. coli.
- RepA-WH1 amyloid aggregates promoted bacterial aging, reducing fitness and division cycles.
Conclusions:
- Engineered RepA-WH1 provides a tractable model for studying protein amyloidosis.
- This bacterial model facilitates research into the mechanisms of protein misfolding and its host effects.
- The RepA-WH1 prionoid system offers a simplified system to unravel general protein amyloidosis pathways.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Subviral Agents
Rabies

